Roche drug dramatically reduces bleeds in key hemophilia tests

LONDON (Reuters) - Roche's new hemophilia drug Hemlibra dramatically reduced bleeding in a broad population of hemophilia patients, results from two clinical trials showed on Monday, setting it up to take a dominant market position.